Figure 2From: Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report CA 19-9 levels during treatment. Graphical depiction of the decline in CA 19-9 tumor marker levels during treatment with erlotinib plus gemcitabine and with maintenance erlotinib.Back to article page